Abstract：
Objective To investigate the expression levels of selenoprotein genes in the patients with coronavirus disease 2019 (COVID-19) and the possible regulatory mechanisms.Methods The dataset GSE177477 was obtained from the Gene Expression Omnibus,consisting of a symptomatic group (n=11),an asymptomatic group (n=18),and a healthy control group (n=18).The dataset was preprocessed to screen the differentially expressed genes (DEG) related to COVID-19,and gene ontology functional annotation and Kyoto encyclopedia of genes and genomes enrichment analysis were performed for the DEGs.The protein-protein interaction network of DEGs was established,and multivariate Logistic regression was employed to analyze the effects of selenoprotein genes on the presence/absence of symptoms in the patients with COVID-19.Results Compared with the healthy control,the symptomatic COVID-19 patients presented up-regulated expression of GPX1,GPX4,GPX6,DIO2,TXNRD1,SELENOF,SELENOK,SELENOS,SELENOT,and SELENOW and down-regulated expression of TXNRD2 and SELENON (all P<0.05).The asymptomatic patients showcased up-regulated expression of GPX2,SELENOI,SELENOO,SELENOS,SELENOT,and SELENOW and down-regulated expression of SELP (all P<0.05).The results of multivariate Logistic regression analysis showed that the abnormally high expression of GPX1 (OR=0.067,95%CI=0.005-0.904,P=0.042) and SELENON (OR=56.663,95%CI=3.114-856.999,P=0.006) was the risk factor for symptomatic COVID-19,and the abnormally high expression of SELP was a risk factor for asymptomatic COVID-19 (OR=15.000,95%CI=2.537-88.701,P=0.003).Conclusions Selenoprotein genes with differential expression are involved in the regulation of COVID-19 development.The findings provide a new reference for the prevention and treatment of COVID-19.
目的 探讨硒蛋白基因在新型冠状病毒感染(COVID-19)患者中的表达水平及其可能的调控机制。方法 从基因表达综合数据库获取数据集GSE177477,样本由有症状组(n=11)、无症状组(n=18)和健康对照组(n=18)构成。对数据集进行预处理,筛选出与COVID-19相关的差异表达基因,并进行基因本体功能注释和京都基因与基因组百科全书富集分析,建立差异表达硒蛋白基因的蛋白质-蛋白质相互作用网络,采用多因素Logistic回归分析硒蛋白基因对COVID-19患者是否出现症状的影响。结果 与健康对照组比较,有症状的COVID-19患者中GPX1、GPX4、GPX6、DIO2、TXNRD1、SELENOF、SELENOK、SELENOS、SELENOT、SELENOW基因表达均升高,TXNRD2、SELENON基因表达均下降(P均<0.05);无症状的COVID-19患者中GPX2、SELENOI、SELENOO、SELENOS、SELENOT、SELENOW基因表达均升高,SELP基因表达下降(P均<0.05)。多因素Logistic回归分析结果显示,GPX1(OR=0.067,95%CI=0.005~0.904,P=0.042)、SELENON(OR=56.663,95%CI=3.114~856.999,P=0.006)基因的异常高表达是有症状COVID-19患者的影响因素,SELP基因的异常高表达是无症状COVID-19患者的危险因素(OR=15.000,95%CI=2.537~88.701,P=0.003)。结论 硒蛋白基因的差异表达参与调控COVID-19疾病的发生发展,为COVID-19的预防和治疗提供新的参考依据。.
目的 探讨硒蛋白基因在新型冠状病毒感染(COVID-19)患者中的表达水平及其可能的调控机制。方法 从基因表达综合数据库获取数据集GSE177477,样本由有症状组(n=11)、无症状组(n=18)和健康对照组(n=18)构成。对数据集进行预处理,筛选出与COVID-19相关的差异表达基因,并进行基因本体功能注释和京都基因与基因组百科全书富集分析,建立差异表达硒蛋白基因的蛋白质-蛋白质相互作用网络,采用多因素Logistic回归分析硒蛋白基因对COVID-19患者是否出现症状的影响。结果 与健康对照组比较,有症状的COVID-19患者中GPX1、GPX4、GPX6、DIO2、TXNRD1、SELENOF、SELENOK、SELENOS、SELENOT、SELENOW基因表达均升高,TXNRD2、SELENON基因表达均下降(P均<0.05);无症状的COVID-19患者中GPX2、SELENOI、SELENOO、SELENOS、SELENOT、SELENOW基因表达均升高,SELP基因表达下降(P均<0.05)。多因素Logistic回归分析结果显示,GPX1(OR=0.067,95%CI=0.005~0.904,P=0.042)、SELENON(OR=56.663,95%CI=3.114~856.999,P=0.006)基因的异常高表达是有症状COVID-19患者的影响因素,SELP基因的异常高表达是无症状COVID-19患者的危险因素(OR=15.000,95%CI=2.537~88.701,P=0.003)。结论 硒蛋白基因的差异表达参与调控COVID-19疾病的发生发展,为COVID-19的预防和治疗提供新的参考依据。.
摘要：
暂无翻译
